|Application No.||Application Title||Issue Date|
|20130060030||PROCESS FOR THE PREPARATION OF HIGHLY PURE CRYSTALLINE IMATINIB BASE|
A process for the preparation of highly pure crystalline imatinib base form- N of Formula (I) is disclosed. Imatinib base of this invention is suitable for conversion to pharmaceutically acceptable salts.
|20130059889||ANHYDROUS LENALIDOMIDE FORM-I|
Anhydrous polymorphic form-I of anti cancer drug, Lenalidomide whose chemical name is 3-(4-amino-1-oxo-1,3-dihydro-isoindole-2-yl)-piperidine-2,6-dione, is disclosed. Alternate methods for making anhydrous polymorphic form-I of Lenalidomide are also disclosed....
|20120329810||IMATINIB MESYLATE ORAL PHARMACEUTICAL COMPOSITION AND PROCESS FOR PREPARATION THEREOF|
The invention relates to an oral pharmaceutical composition comprising, greater than 80% of Imatinib, by weight based on the total weight of the composition and the process for preparation thereof....
|20120172380||NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT|
The invention relates to substituted 4-(tetrazol-5-yl)-quinazoline derivatives of the formula-I,
or pharmaceutically acceptable salts thereof, which possess anti-proliferative activity such as anti-cancer act...